VDI
ALNY icon

Vaughan David Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vaughan David Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,700
Closed -$204K – 153
2015
Q2 		$204K Sell
1,700
-300
-15% -$35.9K 0.01% 149
2015
Q1 		$209K Buy
+2,000
New +$203K 0.01% 149

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Vaughan David Investments's ALNY Position: Q3 2015 in Review

Vaughan David Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2015, closing a stake of 1,700 shares — an estimated $204K sold.

Vaughan David Investments first reported a position in ALNY in Q1 2015 and held it in 2 quarters. The position peaked at $209K in Q1 2015. 258 funds tracked by Wall St. Rank hold ALNY as of Q3 2015.

  • Vaughan David Investments reported no remaining Alnylam Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Vaughan David Investments sold 1,700 Alnylam Pharmaceuticals shares in Q3 2015, an estimated $204K.
  • Vaughan David Investments first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Vaughan David Investments's Alnylam Pharmaceuticals position peaked at $209K in Q1 2015.
  • 258 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2015.

Based on Vaughan David Investments's 13F filing for Q3 2015, filed 17 Nov 2015.